Renzapride

Renzapride
Identifiers
	IUPAC name 4-amino-N-[(4S,5S)-1-azabicyclo[3.3.1]non-4-yl]-5-chloro-2-methoxybenzamide;
CAS Number	109872-41-5;
PubChem CID	3086547;
CompTox Dashboard (EPA)	DTXSID301318522 ;
Chemical and physical data
Formula	C16H22ClN3O2
Molar mass	323.818 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=CC(=C(C=C1C(=O)N[C@H]2CCN3CCC[C@H]2C3)Cl)N;

Renzapride is a gastroprokinetic agent and antiemetic which acts as a full 5-HT₄ full agonist and 5-HT₃ antagonist.^[1]^[2] It also functions as a 5-HT_2B antagonist and has some affinity for the 5-HT_2A and 5-HT_2C receptors, though it is unlikely that these properties contribute to its therapeutic effects.^[1]

Renzapride was being developed by Alizyme plc of the United Kingdom.

Clinical trials

Renzapride was being investigated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). It is also potentially effective for irritable bowel syndrome with alternating stool pattern (IBS-A). It is being developed by Alizyme plc of the United Kingdom.

As of 23 April 2008, Alizyme ceased all development of renzapride, after a Phase III trial in the U.S. did not show enough efficacy over placebo to justify further development.^[3]

References

^ ^a ^b Meyers NL, Hickling RI. (2008). "Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome". Drugs R D. 9 (1): 37–63. PMID 18095752.
^ Camilleri M., McKinzie S., Fox J., Foxx-Orenstein A., Burton D., Thomforde G., Baxter K. and Zinsmeister A. R. (2004). "Effect of Renzapride on Transit in Constipation-Predominant Irritable Bowel Syndrome", Clin. Gastroent. and Hepatology; 2:895-904
^ "Results from Renzapride" (Press release). Alizyme plc. 23 April 2008. Retrieved 7 May 2009.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[pmid18095752-1] Meyers NL, Hickling RI. (2008). "Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome". Drugs R D. 9 (1): 37–63. PMID 18095752.

[2] Camilleri M., McKinzie S., Fox J., Foxx-Orenstein A., Burton D., Thomforde G., Baxter K. and Zinsmeister A. R. (2004). "Effect of Renzapride on Transit in Constipation-Predominant Irritable Bowel Syndrome", Clin. Gastroent. and Hepatology; 2:895-904

[developmenthalted-3] "Results from Renzapride" (Press release). Alizyme plc. 23 April 2008. Retrieved 7 May 2009.

[1]

[2]

[3]